Form 10-Q Pacira BioSciences, Inc. For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
- SanDisk upgraded at JPMorgan after investor day; shares climb
Pacira Pharmaceuticals (PCRX) PT Lowered to $30 at Jefferies
August 1, 2024 3:59 PM EDTJefferies analyst Glen Santangelo lowered the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $30.00 (from $36.00) while maintaining a Buy rating.
The analyst comments "Updating model to reflect 2Q results. Overall, we think NT results remain overshadowed by the pending court ruling... More
Pacira Pharmaceuticals (PCRX) PT Lowered to $37 at RBC Capital
July 31, 2024 6:24 AM EDTRBC Capital analyst Daniel Busb lowered the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $37.00 (from $42.00) while maintaining a Outperform rating.
The analyst comments "While PCRX continues to execute on delivering positive Exparel numbers through 1H, focus remains squarely on ongoing patent... More
